ID   CCNF_HUMAN              Reviewed;         786 AA.
AC   P41002; B2R8H3; Q96EG9;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   28-JUN-2023, entry version 197.
DE   RecName: Full=Cyclin-F;
DE   AltName: Full=F-box only protein 1;
GN   Name=CCNF; Synonyms=FBX1, FBXO1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, DEVELOPMENTAL STAGE,
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=7813445; DOI=10.1002/j.1460-2075.1994.tb06955.x;
RA   Bai C., Richman R., Elledge S.J.;
RT   "Human cyclin F.";
RL   EMBO J. 13:6087-6098(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7896286; DOI=10.1006/geno.1994.1578;
RA   Kraus B., Pohlschmidt M., Leung A.L.S., Germino G.G., Snarey A.,
RA   Schneider M.C., Reeders S.T., Frischauf A.-M.;
RT   "A novel cyclin gene (CCNF) in the region of the polycystic kidney disease
RT   gene (PKD1).";
RL   Genomics 24:27-33(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH SKP1.
RX   PubMed=8706131; DOI=10.1016/s0092-8674(00)80098-7;
RA   Bai C., Sen P., Hofmann K., Ma L., Goebl M., Harper J.W., Elledge S.J.;
RT   "SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery
RT   through a novel motif, the F-box.";
RL   Cell 86:263-274(1996).
RN   [7]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, DOMAIN, AND INTERACTION
RP   WITH CCNB1.
RX   PubMed=10716937; DOI=10.1093/emboj/19.6.1378;
RA   Kong M., Barnes E.A., Ollendorff V., Donoghue D.J.;
RT   "Cyclin F regulates the nuclear localization of cyclin B1 through a cyclin-
RT   cyclin interaction.";
RL   EMBO J. 19:1378-1388(2000).
RN   [8]
RP   INTERACTION WITH SKP1, AND DEGRADATION.
RX   PubMed=12122006; DOI=10.1074/jbc.m205503200;
RA   Fung T.K., Siu W.Y., Yam C.H., Lau A., Poon R.Y.;
RT   "Cyclin F is degraded during G2-M by mechanisms fundamentally different
RT   from other cyclins.";
RL   J. Biol. Chem. 277:35140-35149(2002).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN THE SCF(CCNF) COMPLEX
RP   WITH SKP1 AND CUL1, INTERACTION WITH CP110, AND MUTAGENESIS OF
RP   35-LEU-PRO-36; MET-309 AND LEU-352.
RX   PubMed=20596027; DOI=10.1038/nature09140;
RA   D'Angiolella V., Donato V., Vijayakumar S., Saraf A., Florens L.,
RA   Washburn M.P., Dynlacht B., Pagano M.;
RT   "SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity through
RT   CP110 degradation.";
RL   Nature 466:138-142(2010).
RN   [10]
RP   FUNCTION, INTERACTION WITH RRM2, SUBCELLULAR LOCATION, INDUCTION BY DNA
RP   DAMAGE, AND MUTAGENESIS OF 35-LEU-PRO-36; MET-309 AND LEU-352.
RX   PubMed=22632967; DOI=10.1016/j.cell.2012.03.043;
RA   D'Angiolella V., Donato V., Forrester F.M., Jeong Y.T., Pellacani C.,
RA   Kudo Y., Saraf A., Florens L., Washburn M.P., Pagano M.;
RT   "Cyclin F-mediated degradation of ribonucleotide reductase M2 controls
RT   genome integrity and DNA repair.";
RL   Cell 149:1023-1034(2012).
RN   [11]
RP   INTERACTION WITH CCP110.
RX   PubMed=22441691; DOI=10.1038/embor.2012.40;
RA   Li J., Kim S., Kobayashi T., Liang F.X., Korzeniewski N., Duensing S.,
RA   Dynlacht B.D.;
RT   "Neurl4, a novel daughter centriole protein, prevents formation of ectopic
RT   microtubule organizing centres.";
RL   EMBO Rep. 13:547-553(2012).
RN   [12]
RP   FUNCTION, INTERACTION WITH MYBL2, AND MUTAGENESIS OF 309-MET-ARG-310.
RX   PubMed=25557911; DOI=10.1038/ncomms6800;
RA   Klein D.K., Hoffmann S., Ahlskog J.K., O'Hanlon K., Quaas M., Larsen B.D.,
RA   Rolland B., Roesner H.I., Walter D., Kousholt A.N., Menzel T., Lees M.,
RA   Johansen J.V., Rappsilber J., Engeland K., Soerensen C.S.;
RT   "Cyclin F suppresses B-Myb activity to promote cell cycle checkpoint
RT   control.";
RL   Nat. Commun. 6:5800-5800(2015).
RN   [13]
RP   FUNCTION, INTERACTION WITH FZR1/CDH1 AND CDC20, DEVELOPMENTAL STAGE,
RP   DOMAIN, UBIQUITINATION, D BOX MOTIFS, AND MUTAGENESIS OF 310-ARG--LEU-313
RP   AND 351-ARG--LEU-354.
RX   PubMed=27653696; DOI=10.1016/j.celrep.2016.08.058;
RA   Choudhury R., Bonacci T., Arceci A., Lahiri D., Mills C.A., Kernan J.L.,
RA   Branigan T.B., DeCaprio J.A., Burke D.J., Emanuele M.J.;
RT   "APC/C and SCF(cyclin F) Constitute a Reciprocal Feedback Circuit
RT   Controlling S-Phase Entry.";
RL   Cell Rep. 16:3359-3372(2016).
RN   [14]
RP   FUNCTION, INTERACTION WITH CDC6 AND CUL1, AND SUBCELLULAR LOCATION.
RX   PubMed=26818844; DOI=10.1038/ncomms10530;
RA   Walter D., Hoffmann S., Komseli E.S., Rappsilber J., Gorgoulis V.,
RA   Soerensen C.S.;
RT   "SCF(Cyclin F)-dependent degradation of CDC6 suppresses DNA re-
RT   replication.";
RL   Nat. Commun. 7:10530-10530(2016).
RN   [15]
RP   INVOLVEMENT IN FTDALS5, VARIANTS FTDALS5 GLY-3; ARG-97; ILE-181; ARG-195;
RP   THR-392; PRO-509; ILE-543; GLY-621; LYS-624 AND THR-772, CHARACTERIZATION
RP   OF VARIANTS FTDALS5 GLY-3; ARG-97; ARG-195; THR-392; PRO-509; GLY-621;
RP   LYS-624 AND THR-772, AND FUNCTION.
RX   PubMed=27080313; DOI=10.1038/ncomms11253;
RA   Williams K.L., Topp S., Yang S., Smith B., Fifita J.A., Warraich S.T.,
RA   Zhang K.Y., Farrawell N., Vance C., Hu X., Chesi A., Leblond C.S., Lee A.,
RA   Rayner S.L., Sundaramoorthy V., Dobson-Stone C., Molloy M.P.,
RA   van Blitterswijk M., Dickson D.W., Petersen R.C., Graff-Radford N.R.,
RA   Boeve B.F., Murray M.E., Pottier C., Don E., Winnick C., McCann E.P.,
RA   Hogan A., Daoud H., Levert A., Dion P.A., Mitsui J., Ishiura H.,
RA   Takahashi Y., Goto J., Kost J., Gellera C., Gkazi A.S., Miller J.,
RA   Stockton J., Brooks W.S., Boundy K., Polak M., Munoz-Blanco J.L.,
RA   Esteban-Perez J., Rabano A., Hardiman O., Morrison K.E., Ticozzi N.,
RA   Silani V., de Belleroche J., Glass J.D., Kwok J.B., Guillemin G.J.,
RA   Chung R.S., Tsuji S., Brown R.H. Jr., Garcia-Redondo A., Rademakers R.,
RA   Landers J.E., Gitler A.D., Rouleau G.A., Cole N.J., Yerbury J.J.,
RA   Atkin J.D., Shaw C.E., Nicholson G.A., Blair I.P.;
RT   "CCNF mutations in amyotrophic lateral sclerosis and frontotemporal
RT   dementia.";
RL   Nat. Commun. 7:11253-11253(2016).
RN   [16]
RP   CHARACTERIZATION OF VARIANT FTDALS5 GLY-621, AND FUNCTION.
RX   PubMed=28852778; DOI=10.1007/s00018-017-2632-8;
RA   Lee A., Rayner S.L., Gwee S.S.L., De Luca A., Shahheydari H.,
RA   Sundaramoorthy V., Ragagnin A., Morsch M., Radford R., Galper J.,
RA   Freckleton S., Shi B., Walker A.K., Don E.K., Cole N.J., Yang S.,
RA   Williams K.L., Yerbury J.J., Blair I.P., Atkin J.D., Molloy M.P.,
RA   Chung R.S.;
RT   "Pathogenic mutation in the ALS/FTD gene, CCNF, causes elevated Lys48-
RT   linked ubiquitylation and defective autophagy.";
RL   Cell. Mol. Life Sci. 75:335-354(2018).
CC   -!- FUNCTION: Substrate recognition component of a SCF (SKP1-CUL1-F-box
CC       protein) E3 ubiquitin-protein ligase complex which mediates the
CC       ubiquitination and subsequent proteasomal degradation of target
CC       proteins (PubMed:20596027, PubMed:22632967, PubMed:27653696,
CC       PubMed:26818844, PubMed:27080313, PubMed:28852778). The SCF(CCNF) E3
CC       ubiquitin-protein ligase complex is an integral component of the
CC       ubiquitin proteasome system (UPS) and links proteasome degradation to
CC       the cell cycle (PubMed:8706131, PubMed:20596027, PubMed:27653696,
CC       PubMed:26818844). Mediates the substrate recognition and the
CC       proteasomal degradation of various target proteins involved in the
CC       regulation of cell cycle progression and in the maintenance of genome
CC       stability (PubMed:20596027, PubMed:22632967, PubMed:27653696,
CC       PubMed:26818844). Mediates the ubiquitination and proteasomal
CC       degradation of CP110 during G2 phase, thereby acting as an inhibitor of
CC       centrosome reduplication (PubMed:20596027). In G2, mediates the
CC       ubiquitination and subsequent degradation of ribonucleotide reductase
CC       RRM2, thereby maintaining a balanced pool of dNTPs and genome integrity
CC       (PubMed:22632967). In G2, mediates the ubiquitination and proteasomal
CC       degradation of CDC6, thereby suppressing DNA re-replication and
CC       preventing genome instability (PubMed:26818844). Involved in the
CC       ubiquitination and degradation of the substrate adapter CDH1 of the
CC       anaphase-promoting complex (APC/C), thereby acting as an antagonist of
CC       APC/C in regulating G1 progression and S phase entry (PubMed:27653696).
CC       May play a role in the G2 cell cycle checkpoint control after DNA
CC       damage, possibly by promoting the ubiquitination of MYBL2/BMYB
CC       (PubMed:25557911). {ECO:0000269|PubMed:20596027,
CC       ECO:0000269|PubMed:22632967, ECO:0000269|PubMed:25557911,
CC       ECO:0000269|PubMed:26818844, ECO:0000269|PubMed:27080313,
CC       ECO:0000269|PubMed:27653696, ECO:0000269|PubMed:28852778,
CC       ECO:0000269|PubMed:8706131}.
CC   -!- SUBUNIT: Component of the SCF(CCNF) complex consisting of CUL1, RBX1,
CC       SKP1 and CCNF (PubMed:20596027). Interacts with SKP1 (PubMed:8706131,
CC       PubMed:12122006). Interacts with CUL1 (PubMed:26818844). Interacts with
CC       CCNB1; interaction is required for nuclear localization of CCNB1
CC       (PubMed:10716937, PubMed:20596027). Interacts with CCP110; this
CC       interaction leads to CCP110 ubiquitination and degradation via the
CC       proteasome pathway (PubMed:22441691). Interacts (via the Cyclin N-
CC       terminal domain) with MYBL2/BMYB (PubMed:25557911). Interacts with
CC       FZR1/CDH1 (via N-terminus) (PubMed:27653696). Interacts with RRM2 (via
CC       Cy motif and when phosphorylated at 'Thr-33'); the interaction occurs
CC       exclusively in G2 and early M (PubMed:22632967). Interacts with CDC6
CC       (via Cy motif); the interaction takes place during G2 and M phase
CC       (PubMed:26818844). {ECO:0000269|PubMed:10716937,
CC       ECO:0000269|PubMed:12122006, ECO:0000269|PubMed:20596027,
CC       ECO:0000269|PubMed:22441691, ECO:0000269|PubMed:22632967,
CC       ECO:0000269|PubMed:25557911, ECO:0000269|PubMed:26818844,
CC       ECO:0000269|PubMed:27653696, ECO:0000269|PubMed:8706131}.
CC   -!- INTERACTION:
CC       P41002; O43303: CCP110; NbExp=9; IntAct=EBI-1207574, EBI-1566217;
CC       P41002; Q13616: CUL1; NbExp=5; IntAct=EBI-1207574, EBI-359390;
CC       P41002; P31350: RRM2; NbExp=12; IntAct=EBI-1207574, EBI-2339245;
CC       P41002; P63208: SKP1; NbExp=6; IntAct=EBI-1207574, EBI-307486;
CC       P41002; P63208-1: SKP1; NbExp=6; IntAct=EBI-1207574, EBI-307497;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10716937,
CC       ECO:0000269|PubMed:22632967, ECO:0000269|PubMed:26818844,
CC       ECO:0000269|PubMed:7813445}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:7813445}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome, centriole {ECO:0000269|PubMed:20596027}.
CC       Note=Localization to the centrosome is rare in S phase cells and
CC       increases in G2 cells. Localizes to both the mother and daughter
CC       centrioles. Localization to centrosomes is not dependent on CP110.
CC       Localizes to the nucleus in G2 phase. {ECO:0000269|PubMed:20596027,
CC       ECO:0000269|PubMed:26818844}.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with expression detected in the
CC       heart, brain, placenta, lung, liver, skeletal muscle, kidney and
CC       pancreas. {ECO:0000269|PubMed:7813445}.
CC   -!- DEVELOPMENTAL STAGE: Appears in S phase, peaks in G2 phase, decreases
CC       in mitosis, lowest in early G1 phase and then accumulates again in late
CC       G1 and S phase (at protein level). {ECO:0000269|PubMed:27653696,
CC       ECO:0000269|PubMed:7813445}.
CC   -!- INDUCTION: Down-regulated in an ATR-dependent manner in response to DNA
CC       damage induced by doxorubicin, camptothecin, UV-C, methyl
CC       methanesulfonate, nocodazole, or gamma-irradiation. Down-regulation in
CC       response to DNA damage is required to allow RRM2 accumulation within
CC       the nucleus and for efficient DNA repair.
CC       {ECO:0000269|PubMed:22632967}.
CC   -!- DOMAIN: The nuclear localization signals mediate the localization to
CC       the nucleus and are required for CCNB1 localization to the nucleus.
CC       {ECO:0000269|PubMed:10716937}.
CC   -!- DOMAIN: The D box motifs 1-5 (amino acid sequence RxxL) are involved in
CC       substrate binding, such as FZR1/CDH1, and may be ubiquitinated.
CC       {ECO:0000269|PubMed:27653696}.
CC   -!- PTM: Degraded when the spindle assembly checkpoint is activated during
CC       the G2-M transition. Degradation depends on the C-terminal PEST
CC       sequence. {ECO:0000269|PubMed:12122006}.
CC   -!- PTM: Phosphorylated just before cells enter into mitosis.
CC       {ECO:0000269|PubMed:7813445}.
CC   -!- PTM: Ubiquitinated by the anaphase-promoting complex (APC/C); leading
CC       to its degradation by the proteasome. {ECO:0000269|PubMed:27653696}.
CC   -!- DISEASE: Frontotemporal dementia and/or amyotrophic lateral sclerosis 5
CC       (FTDALS5) [MIM:619141]: A neurodegenerative disorder characterized by
CC       frontotemporal dementia and/or amyotrophic lateral sclerosis in
CC       affected individuals. There is high intrafamilial variation.
CC       Frontotemporal dementia is characterized by frontal and temporal lobe
CC       atrophy associated with neuronal loss, gliosis, and dementia. Patients
CC       exhibit progressive changes in social, behavioral, and/or language
CC       function. Amyotrophic lateral sclerosis is characterized by the death
CC       of motor neurons in the brain, brainstem, and spinal cord, resulting in
CC       fatal paralysis. FTDALS5 is an autosomal dominant form with age-
CC       dependent penetrance. Penetrance is estimated to be 50% by age 56 and
CC       100% by age 61. {ECO:0000269|PubMed:27080313,
CC       ECO:0000269|PubMed:28852778}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Founding member of the F-box domain protein family,
CC       which obtained its name from cyclin-F. {ECO:0000305|PubMed:8706131}.
CC   -!- MISCELLANEOUS: Member of the cyclin family, however, unlike most
CC       members of the cyclin family, it does not bind or activate a cyclin-
CC       dependent kinase. {ECO:0000305|PubMed:7813445}.
CC   -!- SIMILARITY: Belongs to the cyclin family. Cyclin AB subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U17105; AAB60342.1; -; mRNA.
DR   EMBL; Z36714; CAA85308.1; -; mRNA.
DR   EMBL; AK313371; BAG36170.1; -; mRNA.
DR   EMBL; AC106820; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC012349; AAH12349.1; -; mRNA.
DR   CCDS; CCDS10467.1; -.
DR   PIR; A55501; A55501.
DR   RefSeq; NP_001752.2; NM_001761.2.
DR   AlphaFoldDB; P41002; -.
DR   SMR; P41002; -.
DR   BioGRID; 107339; 2799.
DR   CORUM; P41002; -.
DR   DIP; DIP-44939N; -.
DR   IntAct; P41002; 6.
DR   MINT; P41002; -.
DR   STRING; 9606.ENSP00000380256; -.
DR   iPTMnet; P41002; -.
DR   PhosphoSitePlus; P41002; -.
DR   BioMuta; CCNF; -.
DR   DMDM; 20178283; -.
DR   jPOST; P41002; -.
DR   MassIVE; P41002; -.
DR   MaxQB; P41002; -.
DR   PaxDb; P41002; -.
DR   PeptideAtlas; P41002; -.
DR   ProteomicsDB; 55398; -.
DR   Antibodypedia; 10421; 251 antibodies from 33 providers.
DR   DNASU; 899; -.
DR   Ensembl; ENST00000397066.9; ENSP00000380256.4; ENSG00000162063.13.
DR   GeneID; 899; -.
DR   KEGG; hsa:899; -.
DR   MANE-Select; ENST00000397066.9; ENSP00000380256.4; NM_001761.3; NP_001752.2.
DR   UCSC; uc002cqd.2; human.
DR   AGR; HGNC:1591; -.
DR   CTD; 899; -.
DR   DisGeNET; 899; -.
DR   GeneCards; CCNF; -.
DR   HGNC; HGNC:1591; CCNF.
DR   HPA; ENSG00000162063; Tissue enhanced (lymphoid).
DR   MalaCards; CCNF; -.
DR   MIM; 600227; gene.
DR   MIM; 619141; phenotype.
DR   neXtProt; NX_P41002; -.
DR   OpenTargets; ENSG00000162063; -.
DR   Orphanet; 803; Amyotrophic lateral sclerosis.
DR   PharmGKB; PA26156; -.
DR   VEuPathDB; HostDB:ENSG00000162063; -.
DR   eggNOG; KOG0654; Eukaryota.
DR   GeneTree; ENSGT00810000125541; -.
DR   HOGENOM; CLU_020348_0_0_1; -.
DR   InParanoid; P41002; -.
DR   OMA; HQAKKSC; -.
DR   OrthoDB; 3020936at2759; -.
DR   PhylomeDB; P41002; -.
DR   TreeFam; TF101006; -.
DR   PathwayCommons; P41002; -.
DR   Reactome; R-HSA-8951664; Neddylation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SignaLink; P41002; -.
DR   SIGNOR; P41002; -.
DR   BioGRID-ORCS; 899; 72 hits in 1220 CRISPR screens.
DR   ChiTaRS; CCNF; human.
DR   GeneWiki; CCNF; -.
DR   GenomeRNAi; 899; -.
DR   Pharos; P41002; Tbio.
DR   PRO; PR:P41002; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P41002; protein.
DR   Bgee; ENSG00000162063; Expressed in trabecular bone tissue and 162 other tissues.
DR   ExpressionAtlas; P41002; baseline and differential.
DR   Genevisible; P41002; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005814; C:centriole; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:HPA.
DR   GO; GO:0000307; C:cyclin-dependent protein kinase holoenzyme complex; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0019005; C:SCF ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0010997; F:anaphase-promoting complex binding; IDA:UniProtKB.
DR   GO; GO:0016538; F:cyclin-dependent protein serine/threonine kinase regulator activity; IBA:GO_Central.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0044772; P:mitotic cell cycle phase transition; IBA:GO_Central.
DR   GO; GO:0010826; P:negative regulation of centrosome duplication; IDA:UniProtKB.
DR   GO; GO:0001890; P:placenta development; IEA:Ensembl.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0000320; P:re-entry into mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0000079; P:regulation of cyclin-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0031146; P:SCF-dependent proteasomal ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   CDD; cd20521; CYCLIN_CCNF_rpt1; 1.
DR   CDD; cd22082; F-box_FBXO1; 1.
DR   Gene3D; 1.10.472.10; Cyclin-like; 2.
DR   Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 1.
DR   InterPro; IPR039361; Cyclin.
DR   InterPro; IPR013763; Cyclin-like_dom.
DR   InterPro; IPR036915; Cyclin-like_sf.
DR   InterPro; IPR004367; Cyclin_C-dom.
DR   InterPro; IPR006671; Cyclin_N.
DR   InterPro; IPR036047; F-box-like_dom_sf.
DR   InterPro; IPR001810; F-box_dom.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   PANTHER; PTHR10177:SF496; CYCLIN-F; 1.
DR   PANTHER; PTHR10177; CYCLINS; 1.
DR   Pfam; PF02984; Cyclin_C; 1.
DR   Pfam; PF00134; Cyclin_N; 1.
DR   Pfam; PF00646; F-box; 1.
DR   SMART; SM00385; CYCLIN; 2.
DR   SMART; SM01332; Cyclin_C; 1.
DR   SMART; SM00256; FBOX; 1.
DR   SUPFAM; SSF47954; Cyclin-like; 2.
DR   SUPFAM; SSF81383; F-box domain; 1.
DR   PROSITE; PS00292; CYCLINS; 1.
DR   PROSITE; PS50181; FBOX; 1.
PE   1: Evidence at protein level;
KW   Amyotrophic lateral sclerosis; Cell cycle; Cell division; Cyclin;
KW   Cytoplasm; Cytoskeleton; Disease variant; Mitosis; Neurodegeneration;
KW   Nucleus; Phosphoprotein; Reference proteome; Ubl conjugation;
KW   Ubl conjugation pathway.
FT   CHAIN           1..786
FT                   /note="Cyclin-F"
FT                   /id="PRO_0000080463"
FT   DOMAIN          29..76
FT                   /note="F-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00080"
FT   DOMAIN          288..405
FT                   /note="Cyclin N-terminal"
FT                   /evidence="ECO:0000255"
FT   REGION          564..593
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          582..766
FT                   /note="PEST"
FT   REGION          675..738
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           20..28
FT                   /note="Nuclear localization signal 1"
FT                   /evidence="ECO:0000269|PubMed:10716937"
FT   MOTIF           310..313
FT                   /note="D box 1"
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MOTIF           343..346
FT                   /note="D box 2"
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MOTIF           349..352
FT                   /note="D box 3"
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MOTIF           351..354
FT                   /note="D box 4"
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MOTIF           568..574
FT                   /note="Nuclear localization signal 2"
FT                   /evidence="ECO:0000269|PubMed:10716937"
FT   MOTIF           767..770
FT                   /note="D box 5"
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   COMPBIAS        693..736
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   VARIANT         3
FT                   /note="S -> G (in FTDALS5; unknown pathological
FT                   significance; impaired degradation by the ubiquitin
FT                   proteasome system (UPS); dbSNP:rs944306963)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085177"
FT   VARIANT         97
FT                   /note="K -> R (in FTDALS5; unknown pathological
FT                   significance; impaired degradation by the ubiquitin
FT                   proteasome system (UPS); dbSNP:rs1465313712)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085178"
FT   VARIANT         181
FT                   /note="T -> I (in FTDALS5; unknown pathological
FT                   significance; dbSNP:rs745821656)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085179"
FT   VARIANT         195
FT                   /note="S -> R (in FTDALS5; impaired degradation by the
FT                   ubiquitin proteasome system (UPS); dbSNP:rs1371569927)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085180"
FT   VARIANT         392
FT                   /note="R -> T (in FTDALS5; unknown pathological
FT                   significance; impaired degradation by the ubiquitin
FT                   proteasome system (UPS); dbSNP:rs954539468)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085181"
FT   VARIANT         509
FT                   /note="S -> P (in FTDALS5; unknown pathological
FT                   significance; impaired degradation by the ubiquitin
FT                   proteasome system (UPS); dbSNP:rs760953006)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085182"
FT   VARIANT         543
FT                   /note="T -> I (in FTDALS5; unknown pathological
FT                   significance; dbSNP:rs756914411)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085183"
FT   VARIANT         621
FT                   /note="S -> G (in FTDALS5; increased 'Lys-48'-linked
FT                   polyubiquitination of proteins targeted for proteasomal
FT                   degradation, but no increase in 'Lys-63'-linked
FT                   polyubiquitinated proteins; accumulation of ubiquitinated
FT                   proteins including RRM2 and TARDBP/TDP43; impaired
FT                   autophagosome-lysosome fusion; impaired degradation by the
FT                   ubiquitin proteasome system (UPS); increased levels of
FT                   ubiquitinated autophagy receptor SQSTM1/p62;
FT                   dbSNP:rs778264897)"
FT                   /evidence="ECO:0000269|PubMed:27080313,
FT                   ECO:0000269|PubMed:28852778"
FT                   /id="VAR_085184"
FT   VARIANT         624
FT                   /note="E -> K (in FTDALS5; impaired degradation by the
FT                   ubiquitin proteasome system (UPS); dbSNP:rs771621178)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085185"
FT   VARIANT         772
FT                   /note="I -> T (in FTDALS5; unknown pathological
FT                   significance; impaired degradation by the ubiquitin
FT                   proteasome system (UPS); dbSNP:rs762663630)"
FT                   /evidence="ECO:0000269|PubMed:27080313"
FT                   /id="VAR_085186"
FT   MUTAGEN         35..36
FT                   /note="LP->AA: Impairs interaction with SKP1 and CUL1 and
FT                   prevents degradation of CP110, leading to promote the
FT                   formation of micronuclei. Increased interaction with RRM2
FT                   and lack of RRM2 ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:20596027,
FT                   ECO:0000269|PubMed:22632967"
FT   MUTAGEN         309..310
FT                   /note="MR->AA: Reduces the interaction with MYBL2/BMYB.
FT                   Disrupts the interaction with CDC6. Does not disrupt
FT                   interaction with CUL1."
FT                   /evidence="ECO:0000269|PubMed:25557911,
FT                   ECO:0000269|PubMed:26818844"
FT   MUTAGEN         309
FT                   /note="M->A: Reduced degradation of RRM2 after UV-induced
FT                   DNA-damage. Abolishes the interaction with CP110 and RRM2;
FT                   when associated with A-352."
FT                   /evidence="ECO:0000269|PubMed:20596027,
FT                   ECO:0000269|PubMed:22632967"
FT   MUTAGEN         310..313
FT                   /note="RYIL->AYIA: Reduces the interaction with FZR1/CDH1.
FT                   Reduced ubiquitination. Abolishes the interaction with
FT                   FZR1/CDH1; when associated with 351-R--L-354. Loss of
FT                   ubiquitination and impaired degradation; when associated
FT                   with 351-R--L-354."
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MUTAGEN         343..346
FT                   /note="RRRL->ARRA: Reduces the interaction with FZR1/CDH1."
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MUTAGEN         349..352
FT                   /note="RYRL->AYRA: Reduces the interaction with FZR1/CDH1."
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MUTAGEN         351..354
FT                   /note="RLQL->ALQA: Reduces the interaction with FZR1/CDH1.
FT                   Abolishes the interaction with FZR1/CDH1; when associated
FT                   with 310-R--L-313. Loss of ubiquitination and impaired
FT                   degradation; when associated with 310-R--L-313."
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   MUTAGEN         352
FT                   /note="L->A: Abolishes the interaction with CP110 and RRM2;
FT                   when associated with A-309."
FT                   /evidence="ECO:0000269|PubMed:20596027,
FT                   ECO:0000269|PubMed:22632967"
FT   MUTAGEN         767..770
FT                   /note="RINL->AINA: Reduces the interaction with FZR1/CDH1."
FT                   /evidence="ECO:0000269|PubMed:27653696"
FT   CONFLICT        252
FT                   /note="A -> R (in Ref. 2; CAA85308)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        324
FT                   /note="K -> N (in Ref. 2; CAA85308)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        434
FT                   /note="L -> H (in Ref. 3; BAG36170)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        600
FT                   /note="L -> V (in Ref. 2; CAA85308)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        662
FT                   /note="D -> A (in Ref. 2; CAA85308)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        710
FT                   /note="P -> S (in Ref. 1; AAB60342)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        731
FT                   /note="D -> H (in Ref. 2; CAA85308)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   786 AA;  87640 MW;  ADB2FE41BC708898 CRC64;
     MGSGGVVHCR CAKCFCYPTK RRIRRRPRNL TILSLPEDVL FHILKWLSVE DILAVRAVHS
     QLKDLVDNHA SVWACASFQE LWPSPGNLKL FERAAEKGNF EAAVKLGIAY LYNEGLSVSD
     EARAEVNGLK ASRFFSLAER LNVGAAPFIW LFIRPPWSVS GSCCKAVVHE SLRAECQLQR
     THKASILHCL GRVLSLFEDE EKQQQAHDLF EEAAHQGCLT SSYLLWESDR RTDVSDPGRC
     LHSFRKLRDY AAKGCWEAQL SLAKACANAN QLGLEVRASS EIVCQLFQAS QAVSKQQVFS
     VQKGLNDTMR YILIDWLVEV ATMKDFTSLC LHLTVECVDR YLRRRLVPRY RLQLLGIACM
     VICTRFISKE ILTIREAVWL TDNTYKYEDL VRMMGEIVSA LEGKIRVPTV VDYKEVLLTL
     VPVELRTQHL CSFLCELSLL HTSLSAYAPA RLAAAALLLA RLTHGQTQPW TTQLWDLTGF
     SYEDLIPCVL SLHKKCFHDD APKDYRQVSL TAVKQRFEDK RYGEISQEEV LSYSQLCAAL
     GVTQDSPDPP TFLSTGEIHA FLSSPSGRRT KRKRENSLQE DRGSFVTTPT AELSSQEETL
     LGSFLDWSLD CCSGYEGDQE SEGEKEGDVT APSGILDVTV VYLNPEQHCC QESSDEEACP
     EDKGPQDPQA LALDTQIPAT PGPKPLVRTS REPGKDVTTS GYSSVSTASP TSSVDGGLGA
     LPQPTSVLSL DSDSHTQPCH HQARKSCLQC RPPSPPESSV PQQQVKRINL CIHSEEEDMN
     LGLVRL
//
